Gastritis and dyspepsia: 2 names of one problem? Relations between predominant symptom and syndromal characteristics of upper GI disorders: results of a survey of physicians

Introduction. Chronic gastritis is one of the most common problems in gastroenterology and general medical practice. In this study, we tried to analyze the actions of therapists in relation to patients with symptoms of dyspepsia, to assess how different symptom complex affects the choice of therapy and the diagnostics.

Aim. Identifying the process of a preliminary diagnosis by symptoms, determining the ability of physicians to differentiate clinical syndromes, and determining the approaches to empirical therapy at first visit and following the “test and treat” strategy aimed at identifying the H. pylori infection.

Materials and methods. The study was conducted using the CAWI (Computer-assisted Web Interview) method. Each physician who agreed to participate in the study received a link to take the survey and independently entered the answers to the questions formulated by the researcher. The descriptions of three profiles of adult patients with suspected gastritis diagnosis who applied for the first time were suggested: 1) a patient with a pain syndrome and dyspepsia symptoms; 2) a patient with dyspepsia symptoms; 3) a patient with a pain syndrome.

Results. The study involved 205 physicians from 33 cities of Russia. The most commonly assumed diagnosis was gastritis: 50% of responders suggested it for patient 1, 51% – for patient 2, and 40% – for patient 3. Despite the unambiguous description of the delayed motility symptoms in patients 1 and 2, the most commonly assumed diagnoses did not reflect the presence of a problem. At the same time, physicians did not conduct diagnostic tests for H. pylori infection in case of patients 1 and 3 with obvious symptoms of gastritis. In case of infection, physicians suggest prescribing eradication drugs to each patient, and the most popular pharmacological group suggested were PPIs (91%). However, every tenth physician suggested eradication without PPIs.

Conclusion. The results of the survey indicate a lack of awareness among therapists about the symptoms of delayed motility. This leads to the symptomatic pharmacotherapy, which does not provide the rupture of pathogenetic mechanisms

1. Vialov S.S. Chronic gastritis: clinical variants and threatment. Consilium Medicum. 2017;19(8):103–109. (In Russ.) Available at: https://cyberleninka. ru/article/n/hronicheskiy-gastrit-klinicheskie-varianty-i-lechenie.

2. Simanenkov V.I., Vyalov S.S. Chronic gastritis: instructions for use of medications. Terapevticheskii arkhiv = Therapeutic Archive. 2017;89(8):129–133. https://doi.org/10.17116/terarkh2017898129-133.

3. Laine L., Cohen H., Sloane R., Marin-Sorensen M., Weinstein W.M. Interobserver agreement and predictive value of endoscopic findings for H. pylori and gastritis in normal volunteers. Gastrointest Endosc. 1995;42(5):420–423. https://doi.org/10.1016/s0016-5107(95)70043-9.

4. Ivashkin V.T., Mayev I.V., Sheptulin A.A., Lapina T.L., Trukhmanov A.S., Kartavenko I.M. et al. Diagnosis and treatment of the functional dyspepsia: clinical guidelines of the Russian Gastroenterological Association. Rossiyskiy zhurnal gastroehnterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(1):50–61. (In Russ.) Available at: https://www.gastro-j.ru/jour/article/view/123/98.

5. Talley N.J., Ford A.C. Functional Dyspepsia. N Engl J Med. 2015;373(19):1853–1863. https://doi.org/10.1056/NEJMra1501505.

6. Ford A.C., Marwaha A., Sood R., Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: A meta-analysis. Gut. 2015;64(7):1049–1057. https://doi.org/10.1136/gutjnl-2014-307843.

7. Aziz I., Palsson O.S., Törnblom H., Sperber A.D., Whitehead W.E., Simrén M. Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. Lancet Gastroenterol Hepatol. 2018;3(4):252–262. https://doi.org/10.1016/S2468-1253(18)30003-7.

8. Hantoro I.F., Syam A.F., Mudjaddid E., Setiati S., Abdullah M. Factors associated with health-related quality of life in patients with functional dyspepsia. Health Qual Life Outcomes. 2018;16(1):83. https://doi.org/10.1186/ s12955-018-0913-z.

9. Vanheel H., Carbone F., Valvekens L., Simren M., Tornblom H., Vanuytsel T. et al. Pathophysiological Abnormalities in Functional Dyspepsia Subgroups According to the Rome III Criteria. Am J Gastroenterol. 2017;112(1):132–140. https://doi.org/10.1038/ajg.2016.499.

10. Karamanolis G., Caenepeel P., Arts J., Tack J. Association of the predominant symptom with clinical characteristics and pathophysiological mechanisms in functional dyspepsia. Gastroenterology. 2006;130(2):296–303. https://doi.org/10.1053/j.gastro.2005.10.019.

11. Ly H.G., Weltens N., Tack J., Van Oudenhove L. Acute Anxiety and Anxiety Disorders Are Associated With Impaired Gastric Accommodation in Patients With Functional Dyspepsia. Clin Gastroenterol Hepatol. 2015;13(9):1584–1591.e3. https://doi.org/10.1016/j.cgh.2015.03.032.

12. Quartero A.O., de Wit N.J., Lodder A.C., Numans M.E., Smout A.J., Hoes A.W. Disturbed solid-phase gastric emptying in functional dyspepsia: A metaanalysis. Dig Dis Sci. 1998;43(9):2028–2033. https://doi.org/10.1023/a: 1018803129779.

13. Delgado-Aros S., Camilleri M., Cremonini F., Ferber I., Stephens D., Burton D.D. Contributions of gastric volumes and gastric emptying to meal size and postmeal symptoms in functional dyspepsia. Gastroenterology. 2004;127(6):1685–1694. https://doi.org/10.1053/j.gastro.2004.09.006.

14. Pittayanon R., Yuan Y., Bollegala N.P., Khanna R., Lacy B.E., Andrews C.N. et al. Prokinetics for Functional Dyspepsia: A Systematic Review and Meta-Analysis of Randomized Control Trials. Am J Gastroenterol. 2019;114(2):233–243. https://doi.org/10.1038/s41395-018-0258-6.

15. Oh J.H., Kwon J.G., Jung H.K., Tae C.H., Song K.H., Kang S.J. et al. Clinical practice guidelines for functional dyspepsia in Korea. J Neurogastroenterol Motil. 2020;26(1):29–50. https://doi.org/10.5056/jnm19209.

16. Huang X., Lv B., Zhang S., Fan Y.H., Meng L.N. Itopride therapy for functional dyspepsia: A meta-analysis. World J Gastroenterol. 2012;18(48):7371–7377. https://doi.org/10.3748/wjg.v18.i48.7371.

17. Ford A.C., Moayyedi P., Black C.J., Yuan Y., Veettil S.K., Mahadeva S. et al. Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia. Aliment Pharmacol Ther. 2021;53(1):8–21. https://doi. org/10.1111/apt.16072.

18. Yamawaki H., Futagami S., Wakabayashi M., Sakasegawa N., Agawa S., Higuchi K. et al. Management of functional dyspepsia: state of the art and emerging therapies. Ther Adv Chronic Dis. 2018;9(1):23–32. https://doi. org/10.1177/2040622317725479.

19. Mayev I.V., Samsonov A.A., Bueverov A.O., Kochetov S.A. The place of prokinetics in the latest algorithms for the diagnosis and treatment of functional dyspepsia. RMZh = RMJ. 2010;(9):549. (In Russ.) Available at: https://www. rmj.ru/articles/gastroenterologiya/Mesto_prokinetikov_v_poslednih_algoritmah__diagnostiki_i_lecheniya_funkcionalynoy_dispepsii/#ixzz755z0qR1s.

20. Goyal R.K., Guo Y., Mashimo H. Advances in the physiology of gastric emptying. Neurogastroenterol Motil. 2019;31(4):е13546. https://doi.org/10.1111/ nmo.13546.

21. Minushkin O.N. Chronic gastritis: representations, diagnostics, therapeutic approaches. Meditsinskiy sovet = Medical Council. 2007;(3):71–76. (In Russ.) Available at: https://cyberleninka.ru/article/n/hronicheskiy-gastritpredstavleniya-diagnostika-lechebnye-podhody.